Bavarian Nordic inks license and supply deal with Nuance Pharma

Shares of Denmark-based Bavarian Nordic (OMX: BAVA) were up 4% at 175.05 Danish kroner this morning, as is said it has entered into an exclusive license and supply agreement with Nuance Pharma, a Chinese specialty pharmaceutical company, on the development and commercialization of vaccine candidate MVA-BN RSV against respiratory syncytial virus (RSV) in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries1.

The agreement entails clinical development, including a Phase III trial to support regulatory approval of MVA-BN RSV in China, which will be conducted separately from the company’s own Phase III trial planned for initiation later in the first half of 2022 to support a US Biologics License Application (BLA).

Financial terms of the collaboration